Skip to main content
SpringerLink
Log in

In vitro Pharmacodynamics and PK/PD in Animals

  • Chapter
  • First Online:
Polymyxin Antibiotics: From Laboratory Bench to Bedside

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1145))

Abstract

In the last decade, considerable advancements have been made to identify the pharmacokinetic/pharmacodynamic (PK/PD) index that defines the antimicrobial activity of polymyxins. Dose-fractionation studies performed in hollow-fiber models found that altering the dosing schedule had little impact on the killing or suppression of resistance emergence, alluding to AUC/MIC as the pharmacodynamic index that best describes polymyxin’s activity. For in vivo efficacy, the PK/PD index that was the most predictive of the antibacterial effect of colistin against P. aeruginosa and A. baumannii was ƒAUC/MIC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nielsen EI, Cars O, Friberg LE (2011) Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 55(10):4619–4630

    Article  CAS  Google Scholar 

  2. Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16(2):143–166

    Article  CAS  Google Scholar 

  3. Li J, Nation RL, Turnidge JD et al (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6(9):589–601

    Article  CAS  Google Scholar 

  4. Loutet SA, Mussen LE, Flannagan RS, Valvano MA (2011) A two-tier model of polymyxin B resistance in Burkholderia cenocepacia. Environ Microbiol Rep 3(2):278–285

    Article  CAS  Google Scholar 

  5. Bergen PJ, Li J, Rayner CR, Nation RL (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):1953–1958

    Article  CAS  Google Scholar 

  6. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1–10. quiz 11-12

    Article  CAS  Google Scholar 

  7. MacGowan A, Bowker K (2002) Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int J Antimicrob Agents 19(4):291–298

    Article  CAS  Google Scholar 

  8. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL (2010) Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 51(Suppl 1):S103–S110

    Article  Google Scholar 

  9. Deris ZZ, Yu HH, Davis K et al (2012) The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56(10):5103–5112

    Article  CAS  Google Scholar 

  10. Dudhani RV, Turnidge JD, Nation RL, Li J (2010) fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65(9):1984–1990

    Article  CAS  Google Scholar 

  11. Dudhani RV, Turnidge JD, Coulthard K et al (2010) Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54(3):1117–1124

    Article  CAS  Google Scholar 

  12. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL (2010) Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54(9):3783–3789

    Article  CAS  Google Scholar 

  13. Hagihara M, Housman ST, Nicolau DP, Kuti JL (2014) In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 58(2):874–879

    Article  Google Scholar 

  14. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333–1341

    Article  CAS  Google Scholar 

  15. Nation RL, Li J (2009) Colistin in the 21st century. Curr Opin Infect Dis 22(6):535–543

    Article  CAS  Google Scholar 

  16. Al-Khayyat AA, Aronson AL (1973) Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmnacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs. Chemotherapy 19(2):82–97

    Article  CAS  Google Scholar 

  17. Tam VH, Schilling AN, Vo G et al (2005) Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49(9):3624–3630

    Article  CAS  Google Scholar 

  18. Bulitta JB, Yang JC, Yohonn L et al (2010) Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54(5):2051–2062

    Article  CAS  Google Scholar 

  19. Li J, Turnidge J, Milne R, Nation RL, Coulthard K (2001) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45(3):781–785

    Article  CAS  Google Scholar 

  20. Ly NS, Yang J, Bulitta JB, Tsuji BT (2012) Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56(6):3453–3456

    Article  CAS  Google Scholar 

  21. Rao GG, Ly NS, Haas CE et al (2014) New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 58(3):1381–1388

    Article  Google Scholar 

  22. Bergen PJ, Forrest A, Bulitta JB et al (2011) Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55(11):5134–5142

    Article  CAS  Google Scholar 

  23. Bergen PJ, Tsuji BT, Bulitta JB et al (2011) Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55(12):5685–5695

    Article  CAS  Google Scholar 

  24. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N (2011) Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 55(9):4469–4474

    Article  Google Scholar 

  25. Lora-Tamayo J, Murillo O, Bergen PJ et al (2014) Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother 69(9):2434–2442

    Article  CAS  Google Scholar 

  26. Buyck JM, Tulkens PM, Van Bambeke F (2013) Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob Agents Chemother 57(5):2310–2318

    Article  CAS  Google Scholar 

  27. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW (2008) Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61(3):636–642

    Article  CAS  Google Scholar 

  28. Bozkurt-Guzel C, Gerceker AA (2012) In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa. Indian J Med Microbiol 30(1):34–38

    Article  CAS  Google Scholar 

  29. Owen RJ, Li J, Nation RL, Spelman D (2007) In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59(3):473–477

    Article  CAS  Google Scholar 

  30. Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC (2007) Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 51(9):3431–3433

    Article  CAS  Google Scholar 

  31. Tan CH, Li J, Nation RL (2007) Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 51(9):3413–3415

    Article  CAS  Google Scholar 

  32. Poudyal A, Howden BP, Bell JM et al (2008) In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62(6):1311–1318

    Article  CAS  Google Scholar 

  33. Lim TP, Cai Y, Teo J, et al (2013) In vitro pharmacodynamics of tigecycline alone and in combination with meropenem against extreme drug-resistant Klebsiella pneumoniae with decreased susceptibility to polymyxin B in a hollow fibre infection model. In: 53rd interscience conference on antimicrobial agents and chemotherapy, Denver, Colorado, United States

    Google Scholar 

  34. Teo J, Cai Y, Lim TP, et al (2014) Addition of tigecycline to polymyxin B suppresses polymyxin B-resistant subpopulations of extreme drug-resistant Escherichia coli in a hollow fiber infection model. In: 54th Interscience conference on antimicrobial agents and chemotherapy, Washington, DC, United States

    Google Scholar 

  35. Cai Y, Lim TP, Teo J, et al (2013) In vitro pharmacodynamics of polymyxin B alone and in combination with tigecycline against extreme drug-resistant Enterobacter cloacae with decreased susceptibility to polymyxin B in a hollow fibre infection model. In: 23rd European congress of clinical microbiology and infectious diseases, Berlin, Germany

    Google Scholar 

  36. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V, Giamarellou H (2007) In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 57(4):419–422

    Article  CAS  Google Scholar 

  37. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D (2011) Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 66(4):946–947

    Article  CAS  Google Scholar 

  38. Li J, Rayner CR, Nation RL et al (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50(9):2946–2950

    Article  CAS  Google Scholar 

  39. Tsuji BT, Landersdorfer CB, Lenhard JR et al (2016) Paradoxical effect of Polymyxin B: high drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 60(7):3913–3920

    Article  CAS  Google Scholar 

  40. Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL (2016) Colistin and Polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother 60(7):3921–3933

    Article  CAS  Google Scholar 

  41. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N (2012) In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 56(5):2683–2690

    Article  Google Scholar 

  42. Lu Q, Girardi C, Zhang M et al (2010) Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36(7):1147–1155

    Article  CAS  Google Scholar 

  43. Petrosillo N, Ioannidou E, Falagas ME (2008) Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14(9):816–827

    Article  CAS  Google Scholar 

  44. Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW (2014) In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother 58(6):3541–3546

    Article  Google Scholar 

  45. Hornsey M, Phee L, Longshaw C, Wareham DW (2013) In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 41(3):285–287

    Article  CAS  Google Scholar 

  46. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T (2012) Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 40(4):332–336

    Article  CAS  Google Scholar 

  47. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al (2007) Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29(1):51–55

    Article  CAS  Google Scholar 

  48. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ (2009) Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 33(1):33–39

    Article  CAS  Google Scholar 

  49. Landersdorfer CB, Wang J, Wirth V et al (2017) Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother 73(2):462–468

    Article  Google Scholar 

  50. Lin YW, Zhou Q, Onufrak NJ et al (2017) Aerosolized Polymyxin B for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized Polymyxin B against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 61(8):pii: e00211-17

    Article  Google Scholar 

  51. Giacometti A, Cirioni O, Ghiselli R et al (2002) Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock. J Antimicrob Chemother 49(1):193–196

    Article  CAS  Google Scholar 

  52. Miyajima Y, Hiramatsu K, Mizukami E et al (2008) In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 32(5):437–440

    Article  CAS  Google Scholar 

  53. Moreau JM, Conerly LL, Hume EB et al (2002) Effectiveness of mupirocin and polymyxin B in experimental Staphylococcus aureus, Pseudomonas aeruginosa, and Serratia marcescens keratitis. Cornea 21(8):807–811

    Article  Google Scholar 

  54. Zhai B, Lin X (2013) Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro and in vivo. Int J Antimicrob Agents 41(3):250–254

    Article  CAS  Google Scholar 

  55. Lin YW, Zhou QT, Cheah SE et al (2017) Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung Infection model. Antimicrob Agents Chemother 61(3):pii: e02025-16

    Article  Google Scholar 

  56. Docobo-Perez F, Nordmann P, Dominguez-Herrera J et al (2012) Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents 39(3):251–254

    Article  CAS  Google Scholar 

  57. Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R et al (2010) Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54(3):1165–1172

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Singapore General Hospital, Singapore, Singapore

    Winnie Lee, Yiying Cai, Tze-Peng Lim, Jocelyn Teo & Andrea Lay-Hoon Kwa

  2. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore

    Sonja Courtney Chua & Andrea Lay-Hoon Kwa

  3. Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore

    Andrea Lay-Hoon Kwa

Authors
  1. Winnie Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yiying Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tze-Peng Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jocelyn Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sonja Courtney Chua
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Lay-Hoon Kwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Lay-Hoon Kwa .

Editor information

Editors and Affiliations

  1. Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton Campus, Melbourne, VIC, Australia

    Jian Li

  2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Melbourne, VIC, Australia

    Roger L. Nation

  3. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA

    Keith S. Kaye

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, W., Cai, Y., Lim, TP., Teo, J., Chua, S.C., Kwa, A.LH. (2019). In vitro Pharmacodynamics and PK/PD in Animals. In: Li, J., Nation, R., Kaye, K. (eds) Polymyxin Antibiotics: From Laboratory Bench to Bedside. Advances in Experimental Medicine and Biology, vol 1145. Springer, Cham. https://doi.org/10.1007/978-3-030-16373-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation